Arkolith/Insider Trading/ELVN/Form 4

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Nov 21, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$279K
Net Open-Market Flow
-$279K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 19, 2025Sell(S)12K$22.30$268K903K
Nov 19, 2025Sell(S)492$23.09$11K903K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001967150-25-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML